It is observed that targeting PRC2 leads to the decrease of H3K27me3 and DNA hypomethylation, resulting in the activation of the SFRP1 promoter and subsequent inhibition of CCA proliferation. The gene discussed is SFRP1; the disease is cholangiocarcinoma.